专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070065850A1 Method for diagnosis of heart failure 审中-公开
标题翻译：心力衰竭诊断方法
公开(公告)号：US20070065850A1
公开(公告)日：2007-03-22
申请号：US11501810
申请日：2006-08-10
申请人： Tetuo Minamino , Masatsugu Hori , Ken-ichiro Okada , Masafumi Kitakaze
发明人： Tetuo Minamino , Masatsugu Hori , Ken-ichiro Okada , Masafumi Kitakaze
IPC分类号： C12Q1/68 , G01N33/567
CPC分类号： G01N33/6875 , C12Q1/6883 , C12Q2600/158 , G01N2800/325
摘要： A method for diagnosis of heart failure in a human subject, which comprises the step of: measuring an endoplasmic reticulum (ER)-initiated apoptotic signal such as CHOP in a biological sample originated from the subject is disclosed. According to the invention, by employing the new marker in stead of or in addition to a conventional cardiac marker such as BNP, more accurate diagnosis of heart failure can be attained.
摘要翻译：公开了一种用于诊断人类受试者心脏衰竭的方法，其包括以下步骤：测量源自受试者的生物样品中的内质网（ER）诱导的凋亡信号如CHOP。根据本发明，通过采用新的标记物代替常规心脏标志物例如BNP或除常规心脏标志物如BNP之外，可以更准确地诊断心力衰竭。

2. 发明授权

US07026293B2 Treatment or prophylaxis of ischemic heart disease 有权
标题翻译：治疗或预防缺血性心脏病
公开(公告)号：US07026293B2
公开(公告)日：2006-04-11
申请号：US09752724
申请日：2001-01-03
申请人： Masafumi Kitakaze
发明人： Masafumi Kitakaze
IPC分类号： A61K38/00 , A61K38/24 , C07K14/00
CPC分类号： A61K38/2242
摘要： The present invention provides a pharmaceutical composition and a method for reducing an infarct region resulting from the ischemic necrosis of cells, especially, a pharmaceutical composition and a method for suppressing ischemia-reperfusion injury in the treatment of ischemic heart disease. The pharmaceutical composition and the method utilize a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has the effect of reducing an infarct region. The substance is preferably a natriuretic peptide. The present invention is particularly useful for the treatment or prophylaxis of ischemic disease.
摘要翻译：本发明提供了一种药物组合物和减少由细胞缺血性坏死引起的梗死区域的方法，特别是药物组合物和用于治疗缺血性心脏病的局部缺血再灌注损伤的方法。药物组合物和方法利用作为活性成分的物质，其可以通过作用于利尿钠肽受体而增加细胞内cGMP产生，并且具有减少梗死区域的作用。该物质优选为利尿钠肽。本发明特别可用于治疗或预防缺血性疾病。

3. 发明申请

US20160206662A1 CELL FUSION PROMOTER AND UTILIZATION OF THE SAME 审中-公开
标题翻译：细胞融合促进剂及其利用
公开(公告)号：US20160206662A1
公开(公告)日：2016-07-21
申请号：US14958358
申请日：2015-12-03
申请人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata , Kowa Company, Ltd.
发明人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata
IPC分类号： A61K35/34 , A61K35/28 , A61K31/7076
CPC分类号： A61K35/34 , A61K9/0019 , A61K9/19 , A61K31/7076 , A61K35/12 , A61K35/28 , A61L27/3804 , A61L27/3839 , A61L27/3895 , A61K2300/00
摘要： A regeneration promoter for regenerating tissue with the use of somatic stem cells is provided. Also provided are a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.
摘要翻译：提供了使用体细胞干细胞再生组织的再生促进剂。还提供了包含可在体内安全使用的ATP或其代谢物的细胞融合启动子，在ATP或其代谢物存在下产生融合细胞的方法和用于再生或改善组织或器官功能的相关药物组合物在患有由于损伤或变性引起的功能障碍或功能失调的受试者中。

4. 发明授权

US07897397B2 Cell fusion promoter and utilization of the same 有权
标题翻译：细胞融合启动子和利用相同
公开(公告)号：US07897397B2
公开(公告)日：2011-03-01
申请号：US11658731
申请日：2005-07-12
申请人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata
发明人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata
IPC分类号： C12N15/87 , C07H21/02 , A61K31/70
CPC分类号： A61K35/34 , A61K9/0019 , A61K9/19 , A61K31/7076 , A61K35/12 , A61K35/28 , A61L27/3804 , A61L27/3839 , A61L27/3895 , A61K2300/00
摘要： The present invention provides a regeneration promoter for regenerating tissue with the use of somatic stem cells. The invention also provides a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.
摘要翻译：本发明提供了使用体细胞干细胞再生组织的再生促进剂。本发明还提供了包含可在体内安全使用的ATP或其代谢物的细胞融合启动子，在ATP或其代谢物存在下产生融合细胞的方法和用于再生或改善组织或功能的功能的相关药物组合物患有由于损伤或变性引起的功能障碍或功能衰竭的受试者的器官。

5. 发明申请

US20140044683A1 CELL FUSION PROMOTER AND UTILIZATION OF THE SAME 审中-公开
标题翻译：细胞融合促进剂及其利用
公开(公告)号：US20140044683A1
公开(公告)日：2014-02-13
申请号：US14022983
申请日：2013-09-10
申请人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata
发明人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata
IPC分类号： A61K35/12 , A61K31/7076
CPC分类号： A61K35/34 , A61K9/0019 , A61K9/19 , A61K31/7076 , A61K35/12 , A61K35/28 , A61L27/3804 , A61L27/3839 , A61L27/3895 , A61K2300/00
摘要： The present invention provides a regeneration promoter for regenerating tissue with the use of somatic stem cells. The invention also provides a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.
摘要翻译：本发明提供了使用体细胞干细胞再生组织的再生促进剂。本发明还提供了包含可在体内安全使用的ATP或其代谢物的细胞融合启动子，在ATP或其代谢物存在下产生融合细胞的方法和用于再生或改善组织或功能的功能的相关药物组合物患有由于损伤或变性引起的功能障碍或功能衰竭的受试者的器官。

6. 发明授权

US5571524A Agent for curing ischemic myocardial disease 失效
标题翻译：治疗缺血性心肌病的药物
公开(公告)号：US5571524A
公开(公告)日：1996-11-05
申请号：US473774
申请日：1995-06-06
申请人： Masafumi Kitakaze , Masatsugu Hori , Takenobu Kamada , Hiroshi Nakajima , Akihiro Sekine , Tetsuaki Yamaura
发明人： Masafumi Kitakaze , Masatsugu Hori , Takenobu Kamada , Hiroshi Nakajima , Akihiro Sekine , Tetsuaki Yamaura
IPC分类号： C07H19/207 , A61F2/02 , A61K9/48 , A61K31/52 , A61K31/70 , A61K31/7042 , A61K31/7052 , A61K31/7076 , A61K31/715 , A61P9/08 , A61P9/10
CPC分类号： A61K31/70
摘要： An agent for curing ischemic myocardial disease which contains an effective amount of diadenosine 5',5'"-p.sup.1,p.sup.4 -tetraphosphate (Ap4A) of formula (I): ##STR1## or a pharmaceutically-acceptable salt thereof.
摘要翻译：用于治疗缺血性心肌病的药剂，其含有有效量的式（I）的二腺苷5'，5“ - p1，p4-四磷酸（Ap4A）：其可接受的盐。

7. 发明申请

US20110110903A1 CELL FUSION PROMOTER AND UTILIZATION OF THE SAME 审中-公开
标题翻译：细胞融合促进剂及其利用
公开(公告)号：US20110110903A1
公开(公告)日：2011-05-12
申请号：US13005886
申请日：2011-01-13
申请人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata
发明人： Masafumi Kitakaze , Tetsuo Minamino , Akio Hirata
IPC分类号： A61K35/12 , C12N15/06 , A61K35/28 , A61K35/34 , A61P9/00 , A61P9/10 , A61P9/04 , A61P43/00
CPC分类号： A61K35/34 , A61K9/0019 , A61K9/19 , A61K31/7076 , A61K35/12 , A61K35/28 , A61L27/3804 , A61L27/3839 , A61L27/3895 , A61K2300/00
摘要： It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier.
摘要翻译：旨在提供使用体细胞干细胞再生组织的再生促进剂。还旨在提供在体内可安全使用的细胞融合启动子。也就是说，旨在提供一种包含ATP或其代谢物的细胞融合启动子。包含ATP或其代谢物的细胞融合启动子和在ATP或其代谢物存在下产生融合细胞的方法。通过使用干细胞，用于再生或改善由于损伤或变性而发生功能障碍或功能障碍的组织或器官的功能的药用组合物。该组合物包含ATP或其代谢物和药学上可接受的载体。

8. 发明申请

US20050273871A1 Method for diagnosing arrhythmogenic right ventricular dysplasia 审中-公开
标题翻译：诊断心律失常性右室发育不良的方法
公开(公告)号：US20050273871A1
公开(公告)日：2005-12-08
申请号：US10860601
申请日：2004-06-04
申请人： Yoshihiro Asano , Seiji Takashima , Masafumi Kitakaze
发明人： Yoshihiro Asano , Seiji Takashima , Masafumi Kitakaze
IPC分类号： A01K67/027 , C12Q1/68 , G01N33/68
CPC分类号： G01N33/6875 , A01K2227/105 , A01K2267/03 , G01N2800/325
摘要： A specific strain of KK obese mice was found to show a phenotype peculiar to human arrythomogenic right ventricular dysplasia (ARVD), and Lamrl-functional transposon 1 (Lamr1-tp1) was determined to be responsible for this phenotype. Furthermore, the translation product of Lamr1-tp1 was shown to interact with HP1-alpha. Together with the knowledge that human ARVD loci are reported to exist close to the retroposons of Lamr1 or histone-modulating protein genes, aberrant interaction of mutant-LAMR1 and HP1-alpha seems to be a cause of ARVD. Thus, the present invention relates to methods for diagnosing ARVD. The present invention further relates to an animal model of ARVD, and cells transfected with mutant Lamr1 gene demonstrated to cause ARVD in the animal model. Moreover, the present invention relates to methods of screening for compounds suppressing ARVD using the animal model or the transfected cells.
摘要翻译：发现KK肥胖小鼠的特异性菌株显示了人类发生心律失常的右心室发育不良（ARVD）特有的表型，并确定了Lamr1功能转座子1（Lamr1-tp1）对该表型负责。此外，Lamr1-tp1的翻译产物显示与HP1-α相互作用。与知道人类ARVD基因座据报道存在于接近Lamr1或组蛋白调节蛋白基因的翻新细胞的突变体LAMR1和HP1-α的异常相互作用似乎是ARVD的原因。因此，本发明涉及用于诊断ARVD的方法。本发明还涉及ARVD的动物模型和在动物模型中被证实导致ARVD的突变体Lamr1基因转染的细胞。此外，本发明涉及使用动物模型或转染细胞筛选抑制ARVD的化合物的方法。

9. 发明授权

US5700803A Method for reducing infarct size in subjects afflicted with ischemic heart disease 失效
标题翻译：减少缺血性心脏病患者梗死面积的方法
公开(公告)号：US5700803A
公开(公告)日：1997-12-23
申请号：US570767
申请日：1995-12-12
申请人： Masafumi Kitakaze
发明人： Masafumi Kitakaze
IPC分类号： C07D215/38 , A61K31/495 , A61K31/496 , A61P9/08 , A61P9/10
CPC分类号： A61K31/496
摘要： A method for reducing infarct size in a subject afflicted with ischemic heart disease, is disclosed, wherein said method uses, as the active agent, a carbostyril derivative.
摘要翻译：公开了一种降低患有缺血性心脏病的受试者的梗塞面积的方法，其中所述方法使用喹诺酮衍生物作为活性剂。

10. 发明授权

US09095600B2 Prophylactic and/or therapeutic agent for cardiac infarction 有权
标题翻译：心脏梗塞的预防和/或治疗剂
公开(公告)号：US09095600B2
公开(公告)日：2015-08-04
申请号：US12562887
申请日：2009-09-18
申请人： Tetsuo Minamino , Masafumi Kitakaze , Masatsugu Hori , Hiroyuki Takahama , Hiroshi Kikuchi , Kouichi Hashimoto , Hideo Kobayashi , Ayako Iijima , Daigo Asano
发明人： Tetsuo Minamino , Masafumi Kitakaze , Masatsugu Hori , Hiroyuki Takahama , Hiroshi Kikuchi , Kouichi Hashimoto , Hideo Kobayashi , Ayako Iijima , Daigo Asano
IPC分类号： A61K9/127 , A61K31/7076
CPC分类号： A61K31/7076 , A61K9/127
摘要： The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction.The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.
摘要翻译：本发明涉及用于心肌梗塞的新型预防和/或治疗药物。本发明提供了用于心肌梗塞或心肌缺血 - 再灌注损伤的预防和/或治疗药物，该药物含有保留腺苷的脂质膜结构。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式